KGK. A. Gulenkova

K. A. Gulenkova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


K. A. Gulenkova has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Macroscopic changes in the placenta in obesity

    by K.A. Gulenkova, A.A. Orazmuradov, E.V. Patrina, I.V. Bekbaeva, J.M. Husainova, G.A. Orazmuradova

  • Open Access

    Pathogenesis of obstetric and perinatal complications in metabolic syndrome

    by K. A. Gulenkova, A. A. Orazmuradov, E. V. Mukovnikova, M. B. Khamoshina

    Aim. To describe a pathogenetic rationale for obstetric and perinatal complications associated with metabolic syndrome. Materials and Methods. This is a descriptive review based on original research and review articles on obstetric and perinatal complications in the context of metabolic syndrome, published between 2016 and 2025 and indexed in PubMed, ScienceDirect, and eLibrary databases. The following research methods were employed: internet-based analysis, content analysis, historical method, and descriptive-analytical approach. Results. Obesity and metabolic syndrome have a negative impact on maternal and fetal outcomes. Adipose tissue functions as an active endocrine organ that regulates vascular, metabolic, and inflammatory processes across multiple organ systems, thereby affecting obstetric and perinatal outcomes. Conclusion. The obesity epidemic has drawn attention to adipose tissue as a critical regulator of systemic nutrient and energy homeostasis. In metabolic syndrome, adipose tissue must adapt to excessive lipid load through a variety of strategies, including increasing adipocyte size and number, altering immune cell composition, and reshaping lipid metabolism. Failure to adequately adapt to increased nutritional load results in adipose tissue dysfunction which triggers a cascade of lipotoxic effects on other organs, leading to insulin resistance, diabetes mellitus, and related metabolic complications. Adipose tissue dysfunction is significantly accelerated by the additional metabolic load imposed by pregnancy

  • Open Access

    Clinical and anamnestic characteristics of obese pregnant women

    by K.A. Gulenkova, A.A. Orazmuradov, D.S. Novginov, M.T. Khubetsova, T.N. Zulumyan, E.V. Loginova

    Клинико-анамнестическая характеристика беременных с ожирением

  • Open Access

    Molecular genetic and biochemical markers of preeclampsia in obese women

    by I.V. Bekbaeva, A.A. Orazmuradov, K.A. Gulenkova, I.N. Kostin, D.S. Novginov, M.T. Khubetsova

    Молекулярно-генетические и биохимические маркеры преэклампсии у женщин с ожирением

  • Open Access

    Iron deficiency anemia and anemia of chronic disease – what is known?

    by A. V. Solovyeva, M. A. Spitsyna, P. I. Magomedova, E. Yu. Aleinikova, K. A. Gulenkova, L. A. Chegus, Е. Ю. Алейникова

    Anemia is the most common disease in the world, affecting about 30–40% of people. Children, adolescents, and women are most often affected by anemia. The main causes of true iron deficiency (ID and IDA) are insufficient iron intake, increased iron loss (chronic bleeding), increased iron requirement, and impaired iron absorption (gastrointestinal diseases). Chronic diseases, inflammatory conditions, autoimmune diseases, obesity cause an increase in the synthesis of hepcidin in the liver and block the entry of iron into the bloodstream, leading to functional iron deficiency. Anemia of chronic diseases (ACD) or anemia of chronic inflammation (the second most common anemia) is associated with the fact that iron is present in the body, but the absorption of iron in various areas is limited. Until recently, it was believed that treatment with iron supplements in the absence of iron deficiency does not bring benefit to patients with ACD. The opinion has been repeatedly expressed about the harm of iron therapy, since iron is necessary for the growth of some pathogenic microorganisms and tumor cells. However, the real clinical significance of these mainly theoretical provisions is unknown. Therefore, the prescription of iron preparations for anemia is justified and logical. Ferrous sulfate (ferrous iron) is most often prescribed orally due to its low cost, high bioavailability and effectiveness. The drug Tardiferon, containing iron sulphate 247.25 mg (in terms of iron (II) 80.00 mg), is widely used in patients with IDA and ID, since divalent iron has a high ability to overcome the intestinal barrier by “passive” transport and quickly create high concentrations in the blood, restoring the level of hemoglobin and iron stores in the body. The drug Tardiferon has a relatively low dose of iron – 80 mg with slow-release technology to avoid irritating effects on the intestine, contributing to good tolerability. A number of studies confirmed a high safety profile – patients did not refuse to take the drug due to side effects. Timely examination and identification of patients with anemia allows you to prescribe an effective correction. The drug Tardiferon promotes rapid restoration of hemoglobin and iron stores in the body and has good tolerability.


  • Open Access

    Iron deficiency in pregnant women: effect on offspring neuropsychic development

    by A. V. Solovyeva, E. Yu. Aleynikova, M. A. Spitsyna, K. A. Gulenkova, A. M. Jafarova, Е. Ю. Алейникова

    Increasing evidence indicates that adversities in utero and early childhood can have long-lasting effects on physiological and mental health not only in childhood but also in adulthood. Micronutrient deficiency, and in particular iron deficiency, is one of the most significant factors. Based on literature data, to determine the effect of iron deficiency in pregnant women on the neuropsychological development of infants, as well as to determine a cohort of pregnant women who need iron supplements. The search was conducted in MEDLINE (from PubMed), EMBASE (from OVID), Cochrane Library and ClinicalTrials.gov from 2010 to December 2023 without language restrictions. Data were extracted. Primary outcomes included iron deficiency, serum ferritin less than 15 μg/L in pregnant women, perinatal outcomes, and development of children in infancy. The data of serum ferritin in umbilical cord blood in newborns were compared with the serum ferritin of mothers. Data on iron supplementation and its effect on perinatal outcomes were assessed. Daily oral iron supplementation during pregnancy in women without IDA or ID reduces the incidence of iron deficiency anemia at the woman’s due date, reduces the incidence of iron deficiency in fullterm neonates, and reduces the incidence of morbidity in low-birth-weight infants. Iron supplementation during pregnancy and the postpartum period is a strategy for timely replenishment of ID and prevention of IDA to reduce cerebral iron deficiency in the fetus and newborn. The absence of side effects and high bioavailability, enhanced by ascorbic acid, allow us to recommend SunActive®Fe Bonoferlat as a daily supplement for pregnant and lactating women, according to WHO recommendations.

  • Open Access

    Comparative characteristics of women after surgical treatment for uterine fibroids including myomectomy and hysterectomy

    by A.V. Solovieva, E.Yu. Aleynikova, T.A. Demura, M.A. Spitsyna, K.A. Gulenkova

    Сравнительная характеристика женщин с миомой матки после миомэктомии и гистерэктомии

  • Open Access

    Pregnancy complicated by iron deficiency anemia: does the problem have a solution?

    by A. V. Solovyeva, E. Yu. Aleynikova, K. A. Gulenkova, O. A. Kuznetsova, K. S. Ermolenko, Е. Ю. Алейникова

    Introduction. The problem of iron deficiency anemia by pregnant women remains relevant due to the wide spread of this complication (up to 40%) and requires the search for effective drugs with a minimum number of side effects.Aim. To improve perinatal outcomes in patients with iron deficiency anemia.Materials and methods. A retrospective analysis was done for 2020 of the medical records of patients, including an exchange card and birth histories. The patients were selected by a continuous sampling method. The study was conducted at the clinical base of the Department of Obstetrics and Gynecology with the course of perinatology of the Peoples’ Friendship University of Russia (Head of the Department, Corresponding Member of the Russian Academy of Sciences, Professor V.E. Radzinsky). All the patients (n = 114) were divided into three groups: the first group (n = 54) – a study group, which included pregnant women who had iron deficiency anemia in the II or III trimesters and received antianemic treatment; the second group (n = 30) – pregnant women with iron deficiency anemia (diagnosed in the 2nd trimester) who did not take iron supplements, the third group (n = 30) – a control group of women with normal hemoglobin levels during pregnancy and delivery.Results. The use of ferrous sulfate (Sorbifer durules) at a dose of 200 mg per day by pregnant women with IDA led to the fact that the weight-height parameters in newborns did not differ from those of children from healthy puerperas. At the same time, the volume of blood loss was greater in patients with IDA, however, there were no massive bleedings and moderate IDA in the postpartum period. The level of hemoglobin was significantly higher in women in labor who received ferrous sulfate (Sorbifer Durules) from the II trimester compared with pregnant women who had IDA in the III trimester. Thus, further research and the search for optimal dosages are required, as well as determining the most effective period for the use of iron supplements.Conclusions. Good tolerability and high efficacy of Sorbifer Durules in relation to a significant increase in hemoglobin and the absence of severe complications of pregnancy and childbirth associated with anemia allow us to recommend it for the treatment of IDA in pregnant women and puerperas.